Neogen

Declining Demand And Integration Woes Will Dampen Prospects

AnalystLowTarget

Not Invested

Community Contributor

Published

04 Sep 25

Updated

17 Dec 25

Views

n/a

AnalystLowTarget's Fair Value

n/a

-40.2%

5.0%

-40.2%

5.0%

You can edit this narrative until Dec 18 6:05 PM. Then, changes will post as Updates.

Author's Valuation

US$6.510.8% overvalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on 17 Dec 25

Fair value Increased 30%

NEOG: Future CFO Transition And Guidance Stability Will Support Measured Outlook

Analysts have raised their price target on Neogen from approximately $5.00 to $6.50 per share, citing a slightly lower discount rate, modestly improved revenue trajectory, better profit margin expectations, and a willingness to assign a higher future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025, with outgoing CFO David Naemura supporting the transition through year end.

AnalystLowTarget Fair Value

US$6.5

10.8% overvalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

0.88%

Medical Equipment revenue growth rate

7.21%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.84%

Calculation

US$111.17m

Earnings '28

16.45x

PE Ratio '28

US$1.83b

Market Cap '28

US$1.83b

Market Cap '28

218.37m

No. shares '28

US$8.38

Share Price '28

US$8.38 Share Price '28

Discounted to 2025 @ 8.88% p.a.

US$6.49

Fair Value '25